Best Grants for Cancer Nonprofits in Guam

The NCI Worta McCaskill-Stevens Career Development Award supports new clinicians committed to research in community oncology and cancer prevention. This funding aims to facilitate their transition to independent research careers and advanced funding mechanisms. Scholars can lead independent community-based clinical trials, conduct ancillary studies, or gain valuable research experience, specifically targeting underserved communities. Applications are due by 5:00 PM local time of the applicant's organization.

Clinical scientists pursuing mentored cancer research careers in Guam and other eligible U.S. jurisdictions can access career development funding through the National Institutes of Health. NIH provides support and protected time for underrepresented investigators to undertake intensive, supervised biomedical, behavioral, or translational cancer research, including cancer health disparities, to build toward future independent research project grants.

Clinician-scientists pursuing mentored cancer research careers can apply for career development funding from the National Institutes of Health, including applicants in Guam. Focused on cancer and related biomedical, behavioral, and translational research, this K08 program supports intensive, supervised training for individuals from nationally underrepresented backgrounds, helping them build skills to compete for future independent research project grants.

Cancer and health disparities researchers in Guam and other eligible U.S. locations can seek funding for multi-level or multi-domain interventions to reduce disparities in liver diseases and liver cancer. US Dept. of Health & Human Services: National Institutes of Health supports projects focused on improving outcomes among populations experiencing health disparities.

With a mission to advance cancer research, NIH provides Guam cancer and oncology researchers with funding up to US $1,900,000 for pre-clinical nanotechnology-based diagnostics and therapeutics. Academic or research institutions developing nanoparticle or nano-device cancer interventions that can progress toward NCI translational programs may be strong candidates.

Postdoctoral cancer researchers planning clinical trials in Guam can access funding through the National Institutes of Health’s NCI Pathway to Independence Award (K99/R00). Grants from NIH help oncology and medical training professionals transition from mentored postdoctoral roles to independent, tenure-track or equivalent research positions while building competitive cancer research programs.

The FY26 Peer Reviewed Cancer Research Program's Idea Award promotes innovative, high-risk cancer research initiatives. It supports groundbreaking concepts that advance cancer knowledge, patient care, and treatment options within the Military Health System. Projects must demonstrate creativity and innovation, avoiding incremental advancements. Notably, the Early Career Investigator Option is available to foster the growth of promising new investigators early in their careers. This award aims to make significant contributions to cancer research for Service Members and Veterans.

The DoW Peer Reviewed Cancer Clinical Trial Award supports the rapid initiation of clinical trials aimed at significantly improving cancer treatment. Projects may range from small pilot studies to large-scale phase III trials, focusing on innovative products, drugs, or devices. This award mandates the inclusion of patient advocates and prohibits animal studies, ensuring that all preclinical work is completed prior to the award start date. Regulatory applications must be submitted if required for the proposed trials.

The FY26 Peer Reviewed Cancer Research Program Impact Award promotes significant research aimed at enhancing clinical cancer care. It requires preliminary data to ensure feasibility and emphasizes projects with a strong potential for immediate impact. This funding supports clinical trials and allows for either a single Principal Investigator or a duo of partnering PIs, ensuring that both can contribute distinct aspects of the research. Applications must be carefully coordinated to avoid withdrawal risks.

The NCI Research Specialist Award (R50) supports clinician scientists involved in NCI-funded clinical trials. This funding opportunity encourages the development of stable research careers by providing salary support and autonomy, allowing clinician scientists to contribute to national clinical trial development and implementation. They play a critical role in sustaining the NCI clinical trials network without serving as principal investigators. This award aims to ensure continuity in cancer research careers.

The NCI Research Specialist Award (R50) supports non-tenure track scientists in cancer research who provide essential contributions within laboratories and core facilities. This award aims to enhance research careers for skilled scientists who do not seek independent investigator funding. Eligible candidates must possess an advanced degree, have at least two years of contribution to NCI-funded research, and dedicate a significant portion of their time to this work. The R50 offers salary support and travel funds to recognize and stabilize these vital roles in cancer research.

The Radiation Oncology-Biology Integration Network (ROBIN) Centers, funded by the National Cancer Institute (NCI), aims to enhance national radiation oncology infrastructure through collaborative research. This initiative supports studies on biological responses to radiation treatment in cancer patients, focusing on understanding tumor and tissue changes. By integrating various scientific disciplines and collecting comprehensive data, ROBIN intends to improve cancer care, optimize treatment strategies, and accelerate translational discoveries to enhance patient outcomes.

The Paul Calabresi Career Development Award for Clinical Oncology aims to enhance the training of clinician-scientists in clinical and translational cancer research. This funding opportunity encourages the career growth of researchers but does not permit Scholars to lead independent clinical trials. Instead, it allows participation in clinical trials under the mentorship of an experienced researcher, fostering a collaborative approach to cancer research.

The DoW Rare Cancers Idea Development Award promotes innovative research ideas for rare cancers, encouraging applicants to provide preliminary data and exploratory aims. This funding opportunity, offered by the US DOD: U.S. Army Medical Command, seeks projects with the potential for high-impact findings that can significantly benefit the patient community. It aims to foster new avenues of investigation and support discovery-driven research in the field of rare cancers.

The 2026 Rare Cancers Research Program Resource and Community Development Award aims to enhance rare cancer research through improved resources and datasets. It addresses critical gaps in research resources, communication strategies, and data sharing infrastructures. Key features include engaging patient advocates throughout the research process and ensuring sustainability of community platforms. This funding opportunity emphasizes community building and the dissemination of findings to benefit scientific and patient communities alike.

The NCI Pathway to Independence Award (K99/R00) supports early-stage postdoctoral researchers transitioning to independent faculty positions. This funding opportunity encourages talented individuals with clinical or research doctoral degrees to lead independent clinical trials. Applicants should aim to foster research careers in cancer control, prevention, and data sciences. This initiative provides essential support during the transition from mentored positions to independent research roles, enhancing the pool of independent investigators in cancer research.

The NCI Pathway to Independence Award (K99/R00) supports early-stage postdoctoral researchers aiming to transition to independent faculty positions. It encourages candidates with doctoral degrees in research or clinical fields to apply, particularly those in cancer control and prevention. This funding opportunity facilitates a quick shift from mentored research to independent careers, providing essential support for awardees to establish competitive research programs without leading their own clinical trials.

The National Cancer Institute invites applications for the validation of biomarkers and assays for cancer detection and treatment. This funding opportunity supports both analytical and clinical validation of assays, emphasizing the importance of human samples. The program encourages multi-disciplinary collaboration and aims to enhance the performance and reproducibility of cancer assays across clinical laboratories. Applications are due by 5:00 PM local time during the designated deadlines each year.

The Exploratory Grant Award aims to enhance workforce diversity in basic cancer research by supporting junior and Early Stage Investigators from underrepresented groups in the biomedical and social sciences. This initiative provides essential funding to bridge the gap for researchers completing their training, ensuring they have the resources needed to develop larger grant applications. Applications are due by 5:00 PM local time of the applicant organization, emphasizing the importance of timely submissions.

This funding opportunity aims to enhance the cancer surveillance workforce through education and support for certified Oncology Data Specialists. The initiative will improve the quality and completeness of cancer data collected by the National Program of Cancer Registries. By fostering collaboration and promoting the value of cancer surveillance data, this program seeks to empower public health actions, research, and policy-making, ensuring a robust response to current and future cancer-related challenges.

Research institutions and similar organizations studying tobacco, alcohol, or cannabis policies and their effects on health can apply for funding up to US $275,000 from the National Institutes of Health. Grants from NIH help Guam cancer and health equity researchers partner with community organizations to examine policy impacts on substance use, exposure, and cancer prevention among populations experiencing disparities.

Research institutions and universities in Guam working on cancer and biomedical imaging can access funding through the National Institutes of Health to develop molecular imaging methods for studying inflammation in cancer in vivo. Awards up to US $2,500,000 support integrated pre-clinical and clinical imaging research and cross-field collaboration between cancer scientists and imaging experts.

Cancer research institutions and clinical teams in Guam and other eligible U.S. territories can seek funding to integrate imaging and liquid biopsy tumor monitoring during cancer therapy. Focused on advancing cancer/oncology and biomedical imaging, the National Institutes of Health supports R01 projects that optimize these modalities for assessing treatment response and emerging resistance, with awards up to US $2,500,000.

Research institutions and similar organizations studying tobacco, alcohol, or cannabis policy impacts on cancer-related health equity can apply for up to US $2,500,000 in Guam and across the U.S. NIH provides Guam cancer and health disparities researchers with funding to evaluate policies, engage community partners, and reduce exposure among populations experiencing disparities.

Nonprofit and research organizations developing cancer biomarker assays for detection, diagnosis, prognosis, or treatment response can apply for up to US $275,000 from the National Institutes of Health, including projects in Guam. With a mission to advance cancer research, NIH supports analytical (UH2) and clinical (UH3) validation of high-quality assays using human samples.

Cancer research institutions and clinical laboratories in Guam working on biomarker assays for cancer detection, diagnosis, or treatment response can access funding through the National Institutes of Health. Awards up to US $750,000 support clinical validation of analytically validated molecular, cellular, or imaging markers and harmonization of assay performance across studies and laboratories.

Guam cancer and health-disparities research organizations can access funding through the National Institutes of Health to test clinical trials that expand cancer screening and preventive services. Projects must address barriers and facilitators to screening and follow-up in populations experiencing health disparities, working at multiple levels and in collaboration with community partners and healthcare providers.